Unleashing the potential
of hard-to-deliver drugs

About us

NaDeNo is a SINTEF spin-off building on more than a decade of research on a nanotechnology drug delivery platform designed for unleashing the potential of hard-to-deliver hydrophobic small molecule drugs.

The majority of failures in drug development of small molecules are attributed to low water solubility

The majority of failures in drug development of small molecules are attributed to low water solubility

40%

of drugs with market approval

90%

of molecules in discovery pipeline

are poorly water-soluble

Sources:
Vargason, A.M., Anselmo, A.C. & Mitragotri, S. The evolution of commercial drug delivery technologies. Nat Biomed Eng 5, 951–967 (2021)
Kalepu S, Nekkanti V. Insoluble drug delivery strategies: review of recent advances and business prospects. Acta Pharmaceutica Sinica B 5, 442 (2015)

NaDeNo aims at offering its proprietary platform technology to pharma and biotech companies in need of overcoming drug delivery hurdles of promising drugs

Technology

NaDeNo develops a technology platform of nanoparticles to overcome drug delivery hurdles, with initial internal focus on repurposing of effective drugs in areas of high unmet medical need.

Technology

NaDeNo develops a technology platform of nanoparticles to overcome drug delivery hurdles, with initial internal focus on repurposing of effective drugs in areas of high unmet medical need.

  • Biodegradable and biocompatible
  • Ideal for encapsulating hydrophobic drugs
  • Controlled drug release

  • Encapsulated (non-bound) drug
  • High drug loading capacity

  • Surface can be tailored for intended application and administration
  • Release rate can be controlled
  • Active targeting possible

  • Simple and scalable proprietary manufacturing process

  • Superior efficacy compared to non-encapsulated drug shown in various mouse cancer models
  • Low systemic toxicity
  • Specific tumor accumulation

  • Long shelf stability
  • Colloidally stable in biological fluids and cell culture media

Programs

  • Our lead candidate, PACAB-002, is a proprietary nanoformulation of cabazitaxel encapsulated in polymeric nanoparticles

  • An undisclosed oncology pipeline is advancing in collaboration with SINTEF

  • We offer tailored nanoformulations to pharmaceutical and biotechnology companies in need of advanced solutions to overcome delivery hurdles of hydrophobic small molecule drugs

Click image to enlarge

Lead oncology candidate

PACAB-002

  • PACAB-002 are polymeric nanoparticles encapsulating cabazitaxel

  • Cabazitaxel is highly potent and has an established safety and efficacy profile

  • Preclinical data from various mouse cancer models show:

  • long drug retention time in the peritoneal cavity
  • tumor-specific accumulation
  • even distribution throughout the peritoneal cavity
  • significantly improved treatment effect and reduced side effects compared to free drug

Management team

Management team

Annbjørg Falck

Chief Executive Officer
and Co-founder

Annbjørg Falck is a PharmD from the University of Oslo/University of Southern California, and she holds an MBA from the Open University in UK. She has broad experience from pharmaceutical and biotech industry, spanning from large international companies (GE Healthcare and Pfizer Norway) to pharmacy management (Boots Limited) and smaller Norwegian companies (Pronova Biopharma, Targovax, Zelluna Immunotherapy). Since 2010 she has worked in leadership roles within the field of drug development, with a main focus and enthusiasm for regulatory strategy and execution throughout the journey of bringing drugs through preclinical and clinical development to patients. Prior to co-founding NaDeNo Falck worked as an Entrepreneur in Residence for SINTEF TTO & Venture on the commercialization of SINTEF’s nanomedicine technology, resulting in the establishment of NaDeNo.

Yrr Mørch

Chief Technology Officer
and Co-founder

Yrr Mørch is a nanomedicine specialist and one of the inventors of NaDeNo’s technology. She holds a MSc degree in chemical engineering (sivilingeniør) from The Norwegian University of Science and Technology, specializing in biotechnology. In 2008 she defended her PhD in biopolymer chemistry for which she was awarded as the top PhD thesis from Tekna in 2008. Since 2012 she has been the project leader of numerous national and international research and industry projects, has led the Nanomedicine strategic area at SINTEF and was the lead scientist of NaDeNo’s nanoformulation platform technology. Mørch is author of >40 scientific peer-reviewed publications, inventor of eight patents and has contributed as invited speaker at scientific and popular science conferences, in several newspaper articles, a podcast, and in national TV and radio interviews.

Torgeir Vaage

Chief Financial Officer

Torgeir Vaage holds a MSc from Norges Handelshøyskole (Norway) and a PhD from UC Berkeley in business administration. He has more than 20 years of combined experience from the financing sector and biotech with multiple CFO and CEO roles in early-stage life science companies. Vaage is the former senior equity analyst of ABG Sundal Collier/Handelsbanken and management consultant at AT Kearney.

Mary Reilly

Contract COO

Mary is a Chief Operating officer known for leading & driving big pharma and small biotech portfolio through the entire drug development lifecycle to help change patient lives.

Mary is a focused, resilient senior-level leader recognised for driving and delivering results across small molecule, biologics, and cell therapy products. Known for leading and driving big pharma and small biotech portfolio through the entire drug development lifecycle, delivering operational excellence through effective program management, human capital, CMC, and clinical operations. Especially skilled at leading global operations and driving drug development through to execution into the clinic. Articulate communicator who builds lasting relationships with stakeholders, clients, partners, clinicians, and vendors. Known for building a strong company direction and developing corporate governance. Eligible to function as a QP
under EU Regulation 536/2014.

Mary has a Masters in Pharmaceutical Science, a Master’s in leadership & Organisational Leadership and a Diploma in Company direction & Corporate governance.

Partners, collaborators
and supporters